A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Weekly Procrit Given to Gastric or Rectal Patients

Rectal Cancer Clinical Trial

Official title:

A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Epoetin Alfa Administered Weekly in Patients With Gastric or Rectal Cancers Undergoing Preoperative Chemoradiation Followed by Surgery

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00254436
• Other study ID #: ID00-264
• Status: Terminated
• Phase: Phase 3
• Start date: October 31, 2001
• Est. completion date: June 29, 2004

Study information

• Verified date: October 2018
• Source: M.D. Anderson Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To demonstrate the effectiveness of epoetin alfa on reduction in red blood cell transfusions in gastric and rectal cancer patients undergoing preoperative chemoradiation therapy followed by surgery.

Description:

Anemia and fatigue are common problems in gastric and rectal cancer subjects at the completion of chemoradiation therapy and surgery. Results of several studies in cancer subjects suggest that treatment with epoetin alfa may be effective in maintaining hemoglobin levels, thereby reducing fatigue, decreasing transfusion requirement, and potentially improving quality of life.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 50
• Est. completion date: June 29, 2004
• Est. primary completion date: June 29, 2004
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or female 18 years of age or older

• Must have a confirmed diagnosis of gastric or rectal cancer for whom the treatment plan is preoperative chemoradiation followed by surgery

• Must have a baseline hemoglobin >/= 10 g/dl and < 15 g/dl

• Must have adequate hematologic function

• Must have life expectancy of more than 6 months

• Karnofsky performance status of at least 50%

• Must have adequate renal function

• Patients with reproductive potential must use an adequate contraceptive method during treatment and three months after completing treatment

• Patients must be able to read, understand, and complete the three Quality of Life questionnaires in English.

Exclusion Criteria:

• Prior chemotherapy for patients with rectal cancer

• Gastric cancer patients who have received more than 2 cycles of chemotherapy

• Anemia due to factors other than cancer/chemotherapy

• Patients with prior treatment with epoetin alfa or any investigational forms of erythropoietin within the previous 6 months

• Known hypersensitivity to mammalian-cell derived products or to human albumin

• Pregnant or lactating women

• Untreated Central Nervous System metastases

• Any significant, uncontrolled disease/dysfunction of any of the major organs

• Uncontrolled hypertension or history of uncontrolled cardiac arrhythmias, pulmonary embolism, thrombosis

• New onset or poorly controlled seizures

• History of active second malignancy

• Major infection requiring hospitalization and antibiotics or surgery within 14 days of study entry

• Blood transfusion within 1 month of study entry

• Androgen therapy within 2 months of study entry

Related Conditions & MeSH terms

• Gastrointestinal Cancer
• Gastrointestinal Neoplasms
• Rectal Cancer
• Rectal Neoplasms

Intervention

Drug:
• Procrit (epoetin alfa)
Weekly dose

Locations

Country	Name	City	State
United States	UT MD Anderson Cancer Center	Houston	Texas

Sponsors (2)

Lead Sponsor	Collaborator
M.D. Anderson Cancer Center	Ortho Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Patients with Reduction in Red Blood Cell Transfusions		2 years
Primary	Patient Iron Levels	Iron stores drawn at baseline and every four weeks.	Every 4 weeks

External Links

•   UT MD Anderson Cancer Center website